# US 2016/0257964 A1 · Novel Substitution Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257964 A1
- Document ID: US20160257964A1
- Status: Published application
- Kind: A1
- Application number: 15/069,057
- Filed: 2016-03-14
- Published: 2016-09-08
- Earliest claimed: 2001-02-20
- Assignees: Intrexon Corporation
- Applicants: Intrexon Corporation
- Inventors: Subba Reddy PALLI; Mohan Basavaraju Kumar; Dean Ervin Cress; Ted Tsutomu Fujimoto
- Web page: https://patentgrep.com/patent/US20160257964A1

## CPC

- C12N 15/635: {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of modulating the expression of a gene in a host cell comprising the steps of:
a) introducing into the host cell a gene expression modulation system comprising
i) a first polynucleotide that encodes a first polypeptide comprising: (1) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and 2) a first nuclear receptor ligand binding domain; and
ii) a second polynucleotide that encodes a second polypeptide comprising: 1) a transactivation domain; and 2) a second nuclear receptor ligand binding domain;
wherein one of the first or second nuclear receptor ligand binding domains comprises the amino acid sequence of SEQ ID NO: 1 wherein the amino acid sequence of SEQ ID NO: 1 has
i) a single amino acid substitution mutation at amino acid residue 20, 21, 48, 51, 52, 55, 58, 59, 61, 62, 92, 93, 95, 96, 107, 109, 120, 123, 125, 175, 223, 230, 234, or 238 of SEQ ID NO: 1; or
ii) a double amino acid substitution at amino acid residues 107 and 175 of SEQ ID NO: 1, at amino acid residues 127 and 175 of SEQ ID NO: 1, or at amino acid residues 107 and 127 of SEQ ID NO: 1; or
iii) a triple amino acid substitution mutation at amino acid residues 107, 127 and 175 of SEQ ID NO: 1, at amino acid residues 52, 107 and 175 of SEQ ID NO: 1, or at amino acid residues 96, 107 and 175 of SEQ ID NO: 1; and
b) introducing into the host cell a ligand;
wherein the gene to be modulated is a component of a gene expression cassette comprising:
i) a response element recognized by the DNA binding domain;
ii) a promoter that is activated by the transactivation domain; and
iii) a gene whose expression is to be modulated;
whereby upon introduction of the ligand into the host cell, expression of the gene of b) iii) is modulated.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the ligand is
a) a compound of the formula:
wherein:
E is a (C4-C6)alkyl containing a tertiary carbon or a cyano(C3-C5)alkyl containing a tertiary carbon;
R1 is H, Me, Et, i-Pr, F, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, OH, OMe, OEt, cyclopropyl, CF2CF3, CH═CHCN, allyl, azido, SCN, or SCHF2;
R2 is H, Me, Et, n-Pr, i-Pr, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, Ac, F, Cl, OH, OMe, OEt, O-n-Pr, OAc, NMe2, NEt2, SMe, SEt, SOCF3, OCF2CF2H, COEt, cyclopropyl, CF2CF3, CH═CHCN, allyl, azido, OCF3, OCHF2, O-i-Pr, SCN, SCHF2, SOMe, NH—CN, or joined with R3 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon;
R3 is H, Et, or joined with R2 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon;
R4, R5, and R6 are independently H, Me, Et, F, Cl, Br, formyl, CF3, CHF2, CHC12, CH2F, CH2Cl, CH2OH, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or Set; or
b) an ecdysone, 20-hydroxyecdysone, ponasterone A, muristerone A, an oxysterol, a 22(R) hydroxycholesterol, 24(S) hydroxycholesterol, 25-epoxycholesterol, T0901317, 5-alpha-6-alpha-epoxycholesterol-3-sulfate, 7-ketocholesterol-3-sulfate, farnesol, a bile acid, a 1,1-biphosphonate ester, or a Juvenile hormone III.

### Claim 23 (depends on 21)

The method according to claim 21, further composing introducing into the host cell a second ligand, wherein the second ligand is 9-cis-retinoic acid or a synthetic analog of a retinoic acid.

### Claim at position 5

24-25. (canceled)

### Claim 26 (depends on 21)

The method of claim 21, wherein one or more of said amino acid substitution mutations is selected from the group consisting of E20A, Q21A, F48A, I51A, T52A, T52V, T52I, T52I, T55A, T58A, V59A, L61A, I62A, M92A, M93A, R95A, V96A, V96T, V96D, V96M, V107I, F109A, Y120A, A123F, M125A, R175E, L223A, L230A, L234A, W238A, V107I/R175E, Y127E/R175E, V107I/Y127E, V107I/Y127E/R175E, T52V/V107I/R175E, V96A/V107I/R175E, T52A/V107I/R175E, and V96T/107I/R175E.

### Claim 27 (depends on 21)

The method of claim 21, wherein: said transactivation domain is a VP16 transactivation domain said DNA-binding domain is a GAL4 DNA-binding domain that recognizes said response element; said nuclear receptor ligand binding domain is a Choristoneura fumiferana ecdysone receptor ligand binding domain; and wherein said polynucleotide further encodes a chimeric retinoic X receptor ligand binding domain comprising a first polypeptide fragment and a second polypeptide fragment, wherein the first polypeptide fragment is a vertebrate retinoid X receptor ligand binding domain fragment, and the second polypeptide fragment is an invertebrate retinoid X receptor ligand binding domain fragment.

### Claim 28 (depends on 21)

The method of claim 21, wherein said DNA binding domain is selected from the group consisting of a GAL4 DNA binding domain, a LexA DNA binding domain, a transcription factor DNA binding domain, a steroid/thyroid hormone nuclear receptor superfamily member DNA binding domain and a bacterial LacZ DNA binding domain.

### Claim 29 (depends on 21)

The method of claim 21, wherein said transactivation domain is selected from the group consisting of a steroid/thyroid hormone nuclear receptor transactivation domain, a polyglutamine transactivation domain, a basic or acidic amino acid transactivation domain, a VP16 transactivation domain, a GAL4 transactivation domain, an NF-κB transactivation domain, a p65 transactivation domain and a BP42 transactivation domain.

### Claim 30 (depends on 21)

The method of claim 21, wherein said recombinant gene expression system is contained within a vector.

### Claim 31 (depends on 30)

The method of claim 30, wherein said vector is a plasmid.

### Claim 32 (depends on 30)

The method of claim 30, wherein said vector is an expression vector.

### Claim 33 (depends on 30)

The vector of claim 30, wherein said vector is a viral vector.

### Claim 34 (depends on 33)

The vector of claim 33, wherein said viral vector is an adenovirus vector.

### Claim 35 (depends on 21)

The method of claim 21, wherein said host cell is selected from the group consisting of a bacterial cell, a fungal cell, a yeast cell, a plant cell, an animal cell, a mammalian cell, a mouse cell, and a human cell.

### Claim 36 (depends on 21)

The method of claim 21, wherein said host cell is selected from the group consisting of an Aspergillus cell, a Trichoderma cell, a Saccharomyces cell, a Pichia cell, a Candida cell, a Hansenula cell, a Synechocystis cell, a Synechococcus cell, a Salmonella cell, a Bacillus cell, an Acinetobacter cell, a Rhodococcus cell, a Streptomyces cell, an Escherichia cell, a Pseudomonas cell, a Methylomonas cell, a Methylobacter cell, an Alcaligenes cell, a Synechocystis cell, an Anabaena cell, a Thiobacillus cell, a Methanobacterium cell and a Klebsiella cell.

### Claim 37 (depends on 21)

The method of claim 21, wherein said host cell is a plant cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein said plant cell is selected from the group consisting of an apple cell, an Arabidopsis cell, a bajra cell, a banana cell, a barley cell, a bean cell, a beet cell, a blackgram cell, a chickpea cell, a chili cell, a cucumber cell, an eggplant cell, a favabean cell, a maize cell, a melon cell, a millet cell, a mungbean cell, an oat cell, an okra cell, a Panicum cell, a papaya cell, a peanut cell, a pea cell, a pepper cell, a pigeonpea cell, a pineapple cell, a Phaseolus cell, a potato cell, a pumpkin cell, a rice cell, a sorghum cell, a soybean cell, a squash cell, a sugarcane cell, a sugarbeet cell, a sunflower cell, a sweet potato cell, a tea cell, a tomato cell, a tobacco cell, a watermelon cell, and a wheat cell.

### Claim 39 (depends on 35)

The method of claim 35, wherein said host cell is a mammalian cell.

### Claim 40 (depends on 39)

The method of claim 39, wherein said mammalian cell is selected from the group consisting of a hamster cell, a mouse cell, a rat cell, a rabbit cell, a cat cell, a dog cell, a bovine cell, a goat cell, a cow cell, a pig cell, a horse cell, a sheep cell, a monkey cell, a chimpanzee cell, and a human cell.

### Claim 41 (depends on 40)

The method of claim 40, wherein said mammalian cell is a human cell.

### Claim 42 (depends on 21)

The method of claim 21, wherein said host cell is isolated.

### Claim 43

A method of modulating the expression of a gene in a host cell comprising the steps of:
a) introducing into the host cell a gene expression modulation system comprising a gene expression cassette that is capable of being expressed in a host cell comprising a polynucleotide that encodes a polypeptide comprising:
i) a transactivation domain;
ii) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and
iii) a nuclear receptor ligand binding domain comprising the amino acid sequence of SEQ ID NO: 1 wherein the amino acid sequence of SEQ ID NO: 1 has
1) a single amino acid substitution mutation at amino acid residue 20, 21, 48, 51, 52, 55, 58, 59, 61, 62, 92, 93, 95, 96, 107, 109, 120, 123, 125, 175, 223, 230, 234, or 238 of SEQ ID NO: 1; or
2) a double amino acid substitution mutation, at amino acid residues 107 and 175 of SEQ ID NO: 1, at amino acid residues 127 and 175 of SEQ ID NO: 1, or at amino acid residues 107 and 127 of SEQ ID NO: 1; or
3) a triple amino acid substitution mutation at amino acid residues 107, 127 and 175 of SEQ ID NO: 1, at amino acid residues 52, 107 and 175 of SEQ ID NO: 1, or at amino acid residues 96, 107 and 175 of SEQ ID NO: 1,
b) introducing into the host cell a ligand;
wherein the gene to be modulated is a component of a gene expression cassette comprising:
i) a response element recognized by the DNA binding domain;
ii) a promoter that is activated by the transactivation domain; and
iii) a gene whose expression is to be modulated;
whereby upon introduction of the ligand into the host cell, expression of the gene of b) iii) is modulated.
